Who are Fimasartan/Amlodipine, Rosuvastatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fimasartan-amlodipine-rosuvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fimasartan/Amlodipine, Rosuvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fimasartan/Amlodipine, Rosuvastatin (Fimasartan/Amlodipine, Rosuvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist / Calcium channel blocker / HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist / Calcium channel blocker / HMG-CoA reductase inhibitor (statin) AT1 receptor / L-type calcium channel / HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Fimasartan/Amlodipine, Rosuvastatin (Fimasartan/Amlodipine, Rosuvastatin) — Boryung Pharmaceutical Co., Ltd. This combination drug lowers blood pressure through angiotensin II receptor blockade and calcium channel inhibition, while simultaneously reducing cholesterol via HMG-CoA reductase inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fimasartan/Amlodipine, Rosuvastatin TARGET	Fimasartan/Amlodipine, Rosuvastatin	Boryung Pharmaceutical Co., Ltd	phase 3	Angiotensin II receptor antagonist / Calcium channel blocker / HMG-CoA reductase inhibitor (statin)	AT1 receptor / L-type calcium channel / HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist / Calcium channel blocker / HMG-CoA reductase inhibitor (statin) class)

Boryung Pharmaceutical Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fimasartan/Amlodipine, Rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/fimasartan-amlodipine-rosuvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab